Skip to main content
Clinical Trials/CTRI/2022/09/046025
CTRI/2022/09/046025
Not yet recruiting
未知

A clinical study to evaluate the effect of Pramehhara Kwatha in the management of Madhumeha w.s.r. to Type II Diabetes Mellitus

Principal0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Principal
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Principal

Eligibility Criteria

Inclusion Criteria

  • Patients of type 2 diabetes mellitus having
  • a. Fasting Plasma Glucose \-126 to 200 mg/dl
  • b. PPBS(2\-hour Plasma Glucose Level) ââ?¬â?? 200 to 400 mg/dl
  • c. HbA1C between \- 6\.5% to 9%

Exclusion Criteria

  • Subjects suffering from the complications of diabetes mellitus i.e. Diabetic neuropathy, diabetic nephropathy, diabetic retinopathy etc. which require an urgent treatment.
  • Patients having major medical illness like cancer, concurrent infection like tuberculosis.
  • Patients with uncontrolled hypertension.
  • Patients with established diagnosis of CAD or any other clinically significant cardiovascular disease.
  • Renal dysfunction (defined by eGFR \< 60ml/min calculated by MDRD calculator).
  • Subjects who have completed participation in any other clinical trial during the past 3 months.
  • Subjects with haemoglobin percentage \< 9 gm% for males and \< 8gm% for females.
  • Subjects with concurrent hepatic dysfunction (defined as AST and/or ALT \>3 times of the upper normal limit)
  • Uncontrolled acute pulmonary dysfunction requiring inhalational or systemic steroids.
  • Pregnant/ lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials